Altimmune News

News

0

Ticker

ALT

ISIN

US02155H2004

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Altimmune Eulerpool News

8/2/2024, 2:25:26 PM

Pharma-Trend: Gewichtverlust-Medikamente im Aufschwung

Pharma Trend: Weight Loss Medications on the Rise

Altimmune Stock News

Altimmune is being monitored by journalists and investors worldwide. We gather the latest Altimmune news here.

January 28·
Benzinga
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
January 28·
Benzinga
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 28·
Benzinga
Why F5 Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
January 28·
Benzinga
Reported Earlier, Altimmune Prices $75M Registered Direct Offering Of 17,045,454 Common Shares To Fund Phase 3 MASH Trial Preparation
January 6·
Yahoo
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
January 5·
Benzinga
Why Are Investors Looking At Altimmune Stock?
January 5·
Benzinga
Market-Moving News for January 5th
December 29·
Yahoo
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
December 23·
SeekingAlpha
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
December 22·
SeekingAlpha
Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates
December 19·
Benzinga
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
December 19·
SeekingAlpha
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
December 4·
SeekingAlpha
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company
November 26·
Yahoo
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 14·
SeekingAlpha
Altimmune: Probing Pemvi's MASH Data
November 11·
Benzinga
Altimmune Announces Publication In The Lancet Of 24-Week Efficacy And Safety Data From Ongoing IMPACT Phase 2b Trial Of Pemvidutide In Patients With MASH
November 6·
SeekingAlpha
Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
November 5·
Yahoo
Altimmune to Participate in Two Upcoming Investor Conferences
November 3·
Yahoo
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
November 3·
Benzinga
Altimmune Completes Patient Enrollment In RECLAIM, Phase 2 Clinical Trial Evaluating Pemvidutide In Adults With Alcohol Use Disorder

Altimmune Stock Press Releases

Altimmune regularly publishes news on the company's website that are relevant for investors.

January 4•
Altimmune
Altimmune Appoints Raymond Jordt as Chief Business Officer
December 20•
Altimmune
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
November 22•
Altimmune
Altimmune to Participate at Two Upcoming Investor Conferences
November 10•
Altimmune
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
November 3•
Altimmune
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
October 28•
Altimmune
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
September 28•
Altimmune
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
September 14•
Altimmune
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
August 11•
Altimmune
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
August 4•
Altimmune
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
June 17•
Altimmune
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
June 3•
Altimmune
Altimmune to Participate at Two Upcoming Investor Conferences
May 31•
Altimmune
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
May 20•
Altimmune
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
May 16•
Altimmune
Altimmune to Present at Upcoming Investor Conferences
May 12•
Altimmune
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
May 5•
Altimmune
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
April 1•
Altimmune
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
March 15•
Altimmune
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
March 8•
Altimmune
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
January 31•
Altimmune
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
January 3•
Altimmune
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
December 13•
Altimmune
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
November 22•
Altimmune
Altimmune to Present at Upcoming Investor and Scientific Conferences
November 10•
Altimmune
Altimmune to Present at Upcoming Investor Conferences
November 9•
Altimmune
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
November 3•
Altimmune
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
October 6•
Altimmune
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
October 4•
Altimmune
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
September 29•
Altimmune
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021

Altimmune News 2026

This page contains all current news, analysis and press releases for Altimmune stock (ALT, ISIN: US02155H2004). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Altimmune.

Altimmune Stock

Altimmune Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA.